Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Announces Reverse Stock Split

October 23, 2025

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

October 16, 2025

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

October 15, 2025

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

October 14, 2025

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

October 2, 2025

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

September 18, 2025

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

September 17, 2025

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

September 17, 2025

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

September 16, 2025

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025

1
2
3
…
17
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.